du Cros PAK, Greig J, Cross GB, Cousins C, Berry C, et al.
2023-12-01 • International Journal of Tuberculosis and Lung Disease
2023-12-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND The value, speed of completion and robustness of the evidence generated by TB treatment trials could be improved by implementing standards for best practice.
Gupta-Wright A, den Boon S, MacLean E, Cirillo DM, Cobelens F, et al.
2023-11-01 • Bulletin of the World Health Organization
2023-11-01 • Bulletin of the World Health Organization
The World Health Organization has developed target product profiles containing minimum and optimum targets for key characteristics for tests for tuberculosis treatment monitoring and opt...
Mitnick CD, Rodriguez CA, Hatton ML, Brigden G, Cobelens F, et al.
2016-05-25 • PLOS One
2016-05-25 • PLOS One
INTRODUCTION There are numerous challenges in delivering appropriate treatment for multidrug-resistant tuberculosis (MDR-TB) and the evidence base to guide those practices remains li...
2015-03-05 • Expert Review of Anti-Infective Therapy
2015-03-05 • Expert Review of Anti-Infective Therapy
Children were often the forgotten victims of the global tuberculosis (TB) epidemic, neglected by traditional TB services as well as maternal and child health initiatives. Luckily this is...
Nachman S, Ahmed AO, Amanullah F, Becerra M, Botgros R, et al.
2015-06-01 • Lancet Infectious Diseases
2015-06-01 • Lancet Infectious Diseases
Children younger than 18 years account for a substantial proportion of patients with tuberculosis worldwide. Available treatments for paediatric drug-susceptible and drug-resistant tuber...
Brigden G, Nyang'wa BT, du Cros PAK, Varaine FFV, Hughes J, et al.
2014-01-01 • Bulletin of the World Health Organization
2014-01-01 • Bulletin of the World Health Organization
Fewer than 20% of patients with multidrug-resistant (MDR) tuberculosis are receiving treatment and there is an urgent need to scale up treatment programmes. One of the biggest barriers t...
2020-01-01 • Journal of the International AIDS Society
2020-01-01 • Journal of the International AIDS Society
INTRODUCTION:
Tuberculosis (TB) is a leading cause of mortality among people living with HIV (PLHIV). An invigorated global END TB Strategy seeks to increase efforts in scaling up T...
Cox V, Brigden G, Crespo RH, Lessem E, Lynch S, et al.
2018-04-01 • International Journal of Tuberculosis and Lung Disease
2018-04-01 • International Journal of Tuberculosis and Lung Disease
SETTING The World Health Organization recommended two new drugs, bedaquiline (BDQ) and delamanid (DLM), for the treatment of multidrug-resistant tuberculosis (MDR-TB) in 2013 and 201...
2015-12-01 • International Journal of Tuberculosis and Lung Disease
